Loading...
•
Sep 30, 2023
4DMT Q3 2023 Earnings Report
Reported financial results and provided operational highlights for the third quarter of 2023.
Key Takeaways
4DMT reported a net loss of $10.3 million for Q3 2023, compared to a net loss of $25.7 million for Q3 2022. Cash and cash equivalents were approximately $320 million as of September 30, 2023, and the company expects this to fund operations into the first half of 2026.
Advanced 4D-150 development for wet AMD, completing PRISM Phase 2 Dose Expansion enrollment ahead of schedule and enrolling the first patient in the Population Extension cohort.
Received European Medicines Agency’s Priority Medicines (PRIME) designation for 4D-150 for treatment of wet AMD.
Announced positive interim data from 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis; update on FDA interaction expected in Q1 2024.
Gained alignment with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy; interim Phase 1/2 data update expected in Q1 2024.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
The company anticipates key clinical and regulatory milestones over the next few months.